Cellmid Ltd Company Profile

Targeting the global multi-billion-dollar hair loss and anti-aging haircare markets

Cellmid produces évolis®, which has been one of the best selling haircare products of all time on QVC with 33,000 repeat customers in Japan and is poised for further growth. Cellmid is also aiming to commercialise a Rapid Coronavirus Rapid Test in the Australian market after signing a supply agreement with Guangzhou Wondfo Biotech.

  • Company
    Cellmid Ltd
  • Website
  • Sector
  • Industry
  • Code
  • Socials

Company Overview

Cellmid Limited is an Australian life sciences company that is commercialising its intellectual property relating to midkine and FGF5 globally. Cellmid’s FGF5 inhibition technology is being held and commercialised under its subsidiary Advangen, which manufactures and sells évolis®.

Cellmid’s midkine antibodies, believed to be one of the most extensive in the world, are being held by its Lyramid subsidiary, which has the potential to treat fibrosis, chronic kidney disease, heart failure and other chronic heart conditions.

Share this profile:

Targeting the multi-billion dollar hair-loss market

Revenues are continuing to grow strongly through the an omni-channel development strategy and geographic expansion.

Sales of évolis® continue to grow up 39% year on year and reaching over A$7million.

Global Market

The hair loss and anti-aging hair care markets are worth US$7bn and US$24bn respectively


Extensive midkine assets have attracted world-class talent for commercialisation

Breaking News

Cellmid have entered into a supply agreement to supply a COVID-19 rapid diagnostic test to the Australian Market. See the announcement here.

The Key to Solving A Global Problem

Hair loss and hair aging can have devastating psychological consequences on individuals. évolis®, with 100% natural actives and no known side-effects, represents a clear alternative for health conscious consumers.

Validated Technology

évolis® is the only clinically proven and scientifically validated topical hair loss product that promotes hair growth and improves hair quality, while also showing no evidence of side-effects to date. The science behind évolis® involves FGF5 inhibition which is known to regulate the hair's growth cycle.

Latest Presentation

Click here to read the company's latest presentation (scroll to the bottom)

A Best Seller...

In Japan, évolis® (under the trade-name Jo-Ju) is a best seller on the popular QVC TV shopping network, with over 33,000 repeat customers in Japan alone.

...with more opportunities for sales growth

Cellmid will continue to expand sales through channel expansion opportunities as well as geographic expansion.

Explained by the CEO

See how Cellmid's Advangen subsidiary is growing revenue.

National Agreement with Priceline

Cellmid continues to execute on its multi-channel strategy by cementing a national trading agreement with API for the ranging of its évolis® hair care products. évolis® will be featured in approximately 400 Priceline Pharmacy stores around Australia.

Read The Announcement

Click here to read more about the Priceline Agreement

300 million + impressions in 2019

évolis® has been featured in publications by key opinion leaders in the health and beauty space, including Vogue, Marie Claire, Cosmopolitan and more. Over 300m impressions have been achieved since the beginning of 2019 with over 100 publications.

How does Cellmid's évolis® work?

évolis® works by targeting FGF5 which is responsible for managing the hair cycle. Cellmid hold various patents over the ingredients and extraction processes for the natural actives necessary to inhibit FGF5.

Midkine Commercialisation

In addition to évolis®, Cellmid's holds midkine assets considered to be the most extensive in the world. World-class talent Bart Wuurman has joined the company with a focus of commercialising these assets. Bart Wuurman was instrumental in executing a €600 million option deal with Pfizer during his tenure as the CEO of AM-Pharma.

Clock icon Information current at 30 March 2020
This section contains information provided by Cellmid Ltd, with the exception of any sections labeled as "risks". Although all due care has been taken, Mawson Graham ("SmallCapInsider") does not warrant the accuracy of the information provided in this section. It is not intended as an offer, invitation solicitation or recommendation with respect to the purchase or sale of any securities. The above information should not be relied upon as the sole representation of any matter that a potential investor should consider in evaluating Cellmid Ltd. Its affiliates or any of its directors, agents, officers or employees do not make any representation or warranty, express or implied, as to or endorsement of, the accuracy or completeness of any information, statements, representations or forecasts contained above, and they do not accept any liability for any statement made in, or omitted from, the above. Prospective investors should make their own independent evaluation of an investment in Cellmid Ltd. This information may contain forward looking statements concerning Cellmid Ltd. Forward-looking statements are not statements of historical fact and actual events and results may differ materially from those described in the forward looking statements as a result of a variety of risks, uncertainties and other factors. Forward-looking statements are inherently subject to business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause the Company’s actual results to differ materially from those expressed or implied in any forward-looking information provided by Cellmid Ltd, or on behalf of Cellmid Ltd. Forward looking statements are based on Cellmid Ltd's beliefs, opinions and estimates. No obligation is assumed to update forward looking statements if these beliefs, opinions and estimates should change or to reflect other future developments.

Company Videos

1 Video

Analyst Commentary

lock-circle icon

Please Sign In to View

(It's free!)

Multiple growth triggers including the commercialisation of Midkine

Written by SmallCapInsider
Published Aug 16, 2019

We believe that Cellmid’s FGF5 inhibition assets give them a compelling USP in the global competitive landscape for the US$7bn hair loss and US$24bn anti-aging haircare markets. Hair loss and poor hair quality are increasingly becoming problems caused by poor lifestyle choices and environmental factors (such as stress and nutritional deficiencies), rather than being driven purely by genetics and the aging process. Of great significance is the fact that 40% of women have visible hair loss by the time they are aged 40, which has serious negative consequences to an individual’s psychological and emotional wellbeing. Also, Cellmid’s products, based on 100% natural actives, should benefit from the shift of consumers towards products which have natural ingredients.

In addition, On the 28th May 2019, Cellmid announced the appointment of Bart Wuurman as CEO of the company’s Lyramid subsidiary. The primary purpose of the appointment is to allow Mr. Wuurman to drive a licensing or partnership agreement for Cellmid’s extensive IP over Midkine antibodies. Notable achievements by Mr. Wuurman include his role as CEO at AM-Pharma where he achieved a €600m option deal with Pfizer.

Key risks include, but are not limited to, the possibility that Cellmid are unable to continue growing sales and is unable to reach profitability for its Advangen subsidiary, and the possibility that its Mikdine assets are not able to be successfully commercialised.

The information within this section has been provided by Mawson Graham and is for general information purposes only and is not intended to reflect any recommendations or financial advice. The information in this section has been prepared without taking into account your objectives, financial situation or needs. For this reason, you should consider the appropriateness of the advice or recommendation in light of your own personal circumstances, relevant risk factors, the nature and extent of your risk of loss, as well as the legal and accounting consequences before acting making an investment or trading decision regarding any Financial Product mentioned herein. While it is believed that all information sourced and contained within this section to be accurate at the time of publication, liability for any errors, omissions, accuracy or completeness of the information (except any statutory liability which cannot be excluded) is specifically excluded by Mawson Graham, its associates, officers, directors, employees and agents. Past performance is not a reliable indicator of future performance. Important Disclosure: Mawson Graham, its directors, associates and employees advise that they may hold securities, may have an interest in and/or earn brokerage, investor relations fees, corporate fees, and other benefits or advantages, either directly or indirectly from client transactions arising from any information mentioned within this section and in documents published within this section.
Mawson Graham
Mawson Graham

News Coverage

Current news mentioning Cellmid Ltd from top publishers around the web.
Powered by  

Key Announcements

Management comments and explanations on key company announcements.
Need a full list of every announcement? Visit ASX

How do I invest?

Considering investing in Cellmid Ltd?
Here's how to get started.
Low Cost Brokerage ASX Cheapest ASX Trading Platform
  1. 1

    Create account

    Open an account with an online broker of your choice. If you do not have an existing broker, consider Mawson Graham's A$9.50 flat fee platform.

    Sign up now »
  2. 2

    Search for ASX:CDY

    On your online investment platform search for the stock ticker code ASX:CDY to bring up the company's shares.

  3. 3

    Buy shares

    Place your order however you wish. If you need advice on buying or selling, you should seek the assistance of a full service financial adviser experienced in small cap equities.